Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor–TRAF6 signaling
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
TRAF-interacting protein with forkhead-associated domain B (TIFAB) is a haploinsufficient gene in del(5q) myelodysplastic syndrome (MDS). Deletion of Tifab results in progressive bone marrow (BM) and blood defects, including skewed hematopoietic stem/progenitor cell (HSPC) proportions and altered myeloid differentiation. A subset of mice transplanted with Tifab knockout (KO) HSPCs develop a BM failure with neutrophil dysplasia and cytopenia. In competitive transplants, Tifab KO HSPCs are out-competed by wild-type (WT) cells, suggesting a cell-intrinsic defect. Gene expression analysis of Tifab KO HSPCs identified dysregulation of immune-related signatures, and hypersensitivity to TLR4 stimulation. TIFAB forms a complex with TRAF6, a mediator of immune signaling, and reduces TRAF6 protein stability by a lysosome-dependent mechanism. In contrast, TIFAB loss increases TRAF6 protein and the dynamic range of TLR4 signaling, contributing to ineffective hematopoiesis. Moreover, combined deletion of TIFAB and miR-146a, two genes associated with del(5q) MDS/AML, results in a cooperative increase in TRAF6 expression and hematopoietic dysfunction. Re-expression of TIFAB in del(5q) MDS/AML cells results in attenuated TLR4 signaling and reduced viability. These findings underscore the importance of efficient regulation of innate immune/TRAF6 signaling within HSPCs by TIFAB, and its cooperation with miR-146a as it relates to the pathogenesis of hematopoietic malignancies, such as del(5q) MDS/AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice
Boldin, M. P., Taganov, K. D., Rao, D. S., Yang, L., Zhao, J. L., Kalwani, M., Garcia-Flores, Y., Luong, M., Devrekanli, A., Xu, J., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101823 · Cited by 861
NF-κB dysregulation in microRNA-146a–deficient mice drives the development of myeloid malignancies
Zhao, J. L., Rao, D. S., Boldin, M. P., Taganov, K. D., O'Connell, R. M., & Baltimore, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105398108 · Cited by 386
Induction of myelodysplasia by myeloid-derived suppressor cells
Chen, X., Eksioglu, E. A., Zhou, J., Zhang, L., Djeu, J., Fortenbery, N., Epling-Burnette, P., Van Bijnen, S., Dolstra, H., Cannon, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67580 · Cited by 316 · cited 1×
“Through noncell autonomous mechanisms, expansion of myeloid derived suppressor cells expressing S100A9 induces MDS in mice by activating TLR signaling (Chen et al., 2013).”
BackgroundPellagatti, A. (2006) · Blood · doi:10.1182/blood-2005-12-4769 · Cited by 209 · cited 2×
“Although HPSC proportions significantly differed between WT and Tifab-deficient mice, the available gene expression data obtained from MDS CD34+ patient samples (Pellagatti et al., 2006) and by qRT-PCR in an independent cohort of MDS patient samples.”
BackgroundBarreyro, L., Will, B., Bartholdy, B., Zhou, L., Todorova, T. I., Stanley, R. F., Ben-Neriah, S., Montagna, C., Parekh, S., Pellagatti, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404699 · Cited by 201
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome
Rhyasen, G. W., Bolanos, L., Fang, J., Jerez, A., Wunderlich, M., Rigolino, C., Mathews, L., Ferrer, M., Southall, N., Guha, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.006 · Cited by 199 · cited 1×
“Lastly, the importance of TRAF6 in primary MDS is described in our recent publication, in which genetic and pharmacologic inhibition of IRAK1 suppresses TRAF6 activation and the MDS clone (Rhyasen et al., 2013a,b).”
BackgroundSelf-citationRole of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS
Schneider, R. K., Ademà, V., Heckl, D., Järås, M., Mallo, M., Lord, A. M., Chu, L. P., McConkey, M. E., Kramann, R., Mullally, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.08.001 · Cited by 188
Cited by
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Sperling, A. S., Gibson, C. J., & Ebert, B. L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.112 · Cited by 678
Therapy-related myeloid neoplasms: when genetics and environment collide
McNerney, M. E., Godley, L. A., & Le Beau, M. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.60 · Cited by 419
Takizawa, H., Fritsch, K., Kovtonyuk, L. V., Saito, Y., Yakkala, C., Jacobs, K., Ahuja, A. K., Lopes, M., Hausmann, A., Hardt, W.-D., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.06.013 · Cited by 273
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
Sallman, D. A., & List, A. (2019) · Blood · doi:10.1182/blood-2018-10-844654 · Cited by 273
miR-146 and miR-155: Two Key Modulators of Immune Response and Tumor Development
Testa, U., Pelosi, E., Castelli, G., & Labbaye, C. (2017) · Non-Coding RNA · doi:10.3390/ncrna3030022 · Cited by 267
Metadata
- Authors
- Varney, M. E., Niederkorn, M., Konno, H., Matsumura, T., Gohda, J., Yoshida, N., Akiyama, T., Christie, S., Fang, J., Miller, D., Jerez, A., Karsan, A., Maciejewski, J. P., Meetei, R. A., Inoue, J.-I., & Starczynowski, D. T.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-10-12
- Volume
- 212
- Issue
- 11
- Pages
- 1967-1985
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2225951295
- Cited by
- 111
- References
- 8
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor–TRAF6 signaling. https://app.cochat.ai/papers/10.1084/jem.20141898
- The paper
- Varney, M. E., Niederkorn, M., Konno, H., Matsumura, T., Gohda, J., Yoshida, N., Akiyama, T., Christie, S., Fang, J., Miller, D., Jerez, A., Karsan, A., Maciejewski, J. P., Meetei, R. A., Inoue, J.-I., & Starczynowski, D. T. (2015). Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor–TRAF6 signaling. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20141898
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.